Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rollover study of DCR-PHXC in primary hyperoxaluria
NL-OMON54596Phase 3Recruiting
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Oct 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH), Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2) and 1 more, sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Annual rate of decline in eGFR in PH1. Started Oct 2019; status: recruiting.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)primary hyperoxaluria type 3 (PH3)
Beyond the preview
Go deeper on NL-OMON54596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54596.